Watch Live

Tweet TWEET

NuVasive(R) Receives Regulatory Shonin Approval to Broaden

NuVasive(R) Receives Regulatory Shonin Approval to Broaden Offering
in Japan 
SAN DIEGO, CA -- (Marketwire) -- 12/17/12 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, announced
today the Japanese approval of the CoRoent Large Impacted (LI) and
CoRoent Large Tapered (LT) titanium alloy implants. The implants are
used in posterior spine fusion procedures and are NuVasive's first
two interbody fusion cages to be approved in Japan. The approvals
further the Company's ability to participate in the world's second
largest spine market with certain cervical solutions and a
comprehensive posterior product offering, which have already been
cleared for use.  
Alex Lukianov, Chairman and CEO of NuVasive, said, "This is an
exciting stepping stone for NuVasive! For several years, we have been
thoughtfully laying the groundwork and making the investments to
support a direct operation in Japan, a market estimated to be close
to $400 million in size. We are proud to see all of those efforts
coming to fruition so that our revenue ramp can begin in earnest at
the start of the first quarter. We look forward to the opportunity to
introduce Japanese surgeons and patients to NuVasive; 
first to our
game changing portfolio of cervical and posterior thoraco-lumbar
solutions, and then, upon further regulatory approval, to our unique
lateral XLIF(R) solution." 
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $7.9
billion global spine market. NuVasive's principal product offering is
based on its Maximum Access Surgery, or MAS(R) platform. The MAS
platform combines several categories of solutions that collectively
minimize soft tissue disruption during spine surgery with maximum
visualization and safe, easy reproducibility for the surgeon: a
proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade
retractor system; a wide variety of specialized implants; and several
biologic fusion enhancers. MAS significantly reduces surgery time and
returns patients to activities of daily living much faster than
conventional approaches. Having redefined spine surgery with the MAS
platform's lateral approach, known as eXtreme Lateral Interbody
Fusion, or XLIF(R), NuVasive has built an entire spine franchise.
With over 75 products today spanning lumbar, thoracic and cervical
applications, the Company will continue to expand and evolve its
offering predicated on its R&D focus and dedication to outstanding
service levels supported by a culture of Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that NuVasive's revenue or earnings projections may turn out to
be inaccurate because of the preliminary nature of the forecasts and
the risk of further adjustment, or unanticipated difficulty in
selling products or generating expected profitability; the uncertain
process of seeking regulatory approval or clearance for NuVasive's
products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require
significant changes to NuVasive's products or clinical studies; the
risk that products may not perform as intended and may therefore not
achieve commercial success; the risk that competitors may develop
superior products or may have a greater market position enabling more
successful commercialization; the risk that additional clinical data
may call into question the benefits of NuVasive's products to
patients, hospitals and surgeons; and other risks and uncertainties
more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's
public filings with the Securities and Exchange Commission are
available at www.sec.gov. NuVasive assumes no obligation to update
any forward-looking statement to reflect events or circumstances
arising after the date on which it was made. 
Contact: 
Michael J. Lambert 
EVP & Chief Financial Officer 
NuVasive, Inc. 
858.909.3394 
investorrelations@nuvasive.com  
Investors:
Stephan Ogilvie 
VP, Corporate Development & Investor Relations 
NuVasive, Inc.
201-322-6515
investorrelations@nuvasive.com  
Media: 
Nicholas S. Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com